Precision Oncology Update: Myriad Oncology™ Expands the MyRisk® Hereditary Cancer Test

15 New Clinically Relevant Genes—Key Implications for Prostate Cancer Treatment

This content is provided on behalf of Myriad Genetics as part of ACRO's Corporate Partnership Program: 

Radiation oncologists treating prostate cancer now have a more powerful tool in their precision medicine arsenal. Myriad Oncology has expanded its flagship MyRisk® Hereditary Cancer Test to include 15 additional clinically relevant genes, making it the only core germline test that includes 100% of the genes most strongly recommended by ASCO.¹

This update brings the total to 63 genes across 11+ cancer types, with the 15 new genes associated with breast, colorectal, endocrine, gastric, lung, ovarian, renal, and skin cancers.

Why It Matters for Radiation Oncologists

As clinical evidence continues to grow, germline mutations in genes like BRCA1, BRCA2, ATM, CHEK2, and others are increasingly influencing how radiation oncologists approach cancer care and leading oncology guidelines now position germline testing as a critical component of cancer care.

Knowing a patient’s mutation status can: • Guide treatment intensity • Predict radiation sensitivity and inform systemic therapy decisions (e.g., PARP inhibitors) • Guide surveillance and risk management strategies • Support family risk assessment and cascade testing

Streamlined Access for Oncology Workflows

The updated MyRisk Test is fully integrated with platforms like EPIC and OncoEMR, making it easy to order tests and review results within existing clinical workflows. Results are also accessible via paper requisitions and the Myriad patient portal.

Patient-First Services and Support

Myriad simplifies identifying patients who meet guideline-based germline testing criteria through the MyGeneHistory® online questionnaire and provides pre- and post-test education from board-certified Genetic Counselors at no additional cost.

Looking Ahead

As precision oncology continues to evolve, germline testing is becoming a cornerstone of personalized cancer care. Myriad’s expanded MyRisk Test ensures radiation oncologists have the most comprehensive, guideline-aligned genetic insights to help support evidence-based decisions across the care continuum.

Learn More: https://myriad.com/

¹Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615. 3. Internal product development data on file at Myriad Genetics, Inc. Last updated 2025.